Cosmos Health (COSM) said its Cana Laboratories unit acquired an international patent application from Cloudpharm and has begun seeking national and regional protection in key markets.
The technology combines early-stage discovery methods with advanced pharmaceutical development approaches, the company said Monday in a statement.
Cana also plans to expand investment in nanotechnology-based platforms for pharmaceutical, nutraceutical, over-the-counter and specialized healthcare products.
The company said the project will integrate the newly acquired IP with Cana's European manufacturing capabilities.
Price: $0.22, Change: $-0.03, Percent Change: -10.53%